Latest stories on NRIX
Nurix Therapeutics management to meet with Piper Sandler
The Fly56 · neutralgeneral
NRx Pharmaceuticals calls NY Times report ‘knowingly false,’ demands retraction
The Fly42 · neutralgeneral
NRx Pharmaceuticals’ Ketafree leads FDA approval race, NY Times reports
The Fly64 · neutralproduct/pr
NRx Pharmaceuticals completes three process validation lots of Ketamine
The Fly58 · neutralproduct/pr
H.C. Wainwright raises Nurix stock price target on strong revenue
Investing.com Analyst Ratings64 · neutralanalyst
NRx receives FDA review letter for Ketamine product requesting minor changes
The Fly58 · neutralproduct/pr
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
StockTitan58 · neutralproduct/pr
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Seeking Alpha74 · bullishanalyst
Nurix Therapeutics price target lowered to $33 from $34 at Truist
The Fly38 · neutralanalyst
Nurix Therapeutics price target lowered to $35 from $36 at RBC Capital
The Fly38 · neutralanalyst
Nurix Therapeutics price target raised to $32 from $28 at Oppenheimer
The Fly64 · neutralanalyst
Nurix Therapeutics price target raised to $36 from $33 at Baird
The Fly64 · neutralanalyst
Nurix Therapeutics price target raised to $41 from $40 at Stifel
The Fly63 · neutralanalyst
Nurix Therapeutics, Inc. (NRIX) files 8-K
SEC 8-K50 · neutralgeneral
Nurix Therapeutics reports Q3 EPS $4.73, consensus $5.11
The Fly34 · bearishearnings
Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M
Business Insider78 · bullishearnings
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire58 · neutralearnings
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Business Insider58 · neutralearnings
Nurix Therapeutics options imply 5.2% move in share price post-earnings
The Fly50 · neutralearnings
Nurix Therapeutics options imply 4.5% move in share price post-earnings
The Fly50 · neutralearnings
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Business Insider63 · neutralproduct/pr
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
GlobeNewswire63 · neutralproduct/pr
Nurix Therapeutics announces second research term extension with Gilead
The Fly63 · neutralproduct/pr
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Business Insider63 · neutralproduct/pr
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
GlobeNewswire63 · neutralproduct/pr